Close

Pharma service provider further expands offerings for clinical development and manufacturing

Related stories

hubXchange Announces Upcoming Series of Exclusive Roundtable Events in San Diego – February 2025

hubXchange, the premier platform for senior-level knowledge exchange in...

Aragen receives Platinum Medal from EcoVadis for its sustainability initiatives

Hyderabad: Aragen Life Sciences, a globally renowned Contract Research,...

Danish protein analysis to revolutionize the biopharma industry’s impurity control

The requirements for quality assurance of biologics are increasing....

Berry Global Healthcare to Showcase New Packaging Innovations at Pharmapack 2025

Berry Global Healthcare, a leader in innovative packaging solutions,...

High demand: Vetter expands production capacities and services offered at its Austrian site

  • Already 14 customer fills completed in the first quarter of 2023
  • More than ten successfully completed customer audits confirm high quality and process standards
  • Vetter underpins commitment to customers in drug development with expansion

Ravensburg, Germany, Rankweil, Austria, 09 May 2023 – Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), continues to drive the expansion of capacities and services for the provision of clinical trial materials: With the implementation of additional equipment for aseptic production and the expansion of storage capacities at the clinical site in Rankweil, Austria, the company is responding to increasing market demand. By the end of 2021, Vetter’s production in Rankweil was up and running, and 17 customer projects have already been won.

Dynamic development of the Rankweil location

Vetter has completed the first year of production in Rankweil successfully and is preparing to further increase production capacities and capabilities on site. With 14 batches already filled in the first quarter of 2023, the number of batches produced in total at the site in 2022 has already been surpassed. The further expansion of the site will make it possible to more than double the production volume by the end of the year.

The use of a second autoclave and washing machine for material preparation will significantly increase cleanroom utilization. Furthermore, the pharmaceutical service provider has doubled the capacity for cold storage by purchasing additional freezers. Vetter is also expanding its customer-oriented service offering – with the implementation of an isolator, powdered substances can now also be processed in Rankweil. Further options for primary packaging materials expand the portfolio for clinical filling.

Dr. Claus Feussner, Senior Vice President, Vetter Development Service, is very satisfied: “In addition to our existing clinical manufacturing facility in Chicago, Rankweil has established itself in a very short time as a strategically important location for us and our partners. Customer service, efficient processes and our high quality standard are the focus.”

Company: Vetter Pharma-Fertigung GmbH & Co. KG


Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the pharmaceutical service provider is also present with its own sales locations in the Asia-Pacific markets of Japan, China, South Korea and Singapore. Around the world, small and large renowned pharma and biotech companies rely on the decades of experience, high quality, modern technologies, reliability, and commitment of more than 6,300 employees. In close partnership with its customers, the Vetter team supplies patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative solutions, Vetter develops prefilled drug-delivery systems together with its customers to continuously improv

Send Enquiry for this story

By submitting this form you are giving a consent to Worldpharmatoday.com to store your submitted information.
See our Privacy Policy to learn more about how we use data.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories